In April, we focussed on IMI projects in the field of pain research. The most widely used drugs used to treat pain have been linked to addiction, or they come with intolerable side effects. In some cases, even opiates do not provide pain relief, leaving no therapeutic option for many people. To speed up the development of newer, non-addictive alternatives that work effectively, pharma companies have come together in IMI projects, helping to drive our understanding the factors that influence the placebo effect, developing standards for preclinical animal models for pain drug research, and harmonising measures for patient-reported pain-related outcomes, among many other efforts. Pain relief is usually top of the list of concerns for patients, and IMI's model of radical collaboration is bringing the reality of new and better pain treatments closer every day.
Researchers tackle the product-agnostic problems that plague pain drug research
Neuropathic pain was classified in a way that stymied research. Not anymore
Placebo response is affected by the drug you *think* you might be taking – especially if it’s an opioid
Machine learning models outperform traditional selection methods for recruiting osteoarthritis trial patients
Receptor identified in the bladder for the first time could spell new drug target for urological diseases